Head-to-head evidence
Albuvirtide vs Lipovirtide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV gp41 · full HIV pipeline
Albuvirtide · Aikening
Marketed by Frontier Biotechnologies
NCT02369965 · Phase 3 · completed
The study randomly assigned 418 participants to an active comparator, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: July 2028 · NCT07727642 (registry estimate)
Lipovirtide
Developed by Shanxi Kangbao Biological Product
NCT06061536 · Phase 2 · completed
The study was randomized and included an active DTG comparator, but it was open-label, enrolled 64 participants across four groups, and used viral suppression as a surrogate laboratory endpoint rather than a hard clinical outcome. Because the primary comparison and its statistical result are not available, the findings cannot be judged as having met or missed the endpoint.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuvirtide's landscape · Lipovirtide's landscape